Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China
    Zhou, Xiwen
    Du, Jianting
    Xu, Guobing
    Chen, Chun
    Zheng, Bin
    Chen, Jiahe
    CANCER MEDICINE, 2022, 11 (23): : 4449 - 4456
  • [22] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
    Hori, Tomoki
    Yamamoto, Kazuhiro
    Ito, Takefumi
    Ikushima, Shigeki
    Omura, Tomohiro
    Yano, Ikuko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
  • [23] Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
    Li, Huiying
    Yu, Tingting
    Huang, Mingmin
    Guo, Aibin
    Qian, Xiaoping
    Yin, Zhenyu
    ONCOTARGETS AND THERAPY, 2019, 12 : 7785 - 7790
  • [24] Critical points in the management of EGFR-mutated non-small cell lung cancer
    Casaluce, Francesca
    Gridelli, Cesare
    JOURNAL OF THORACIC DISEASE, 2022, 14 (06) : 1748 - 1752
  • [25] Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review
    Nargesi, Shahin
    Dolatshahi, Zeinab
    Rezapour, Aziz
    Alipour, Vahid
    Souresrafil, Aghdas
    Farabi, Hiro
    Javadmoosavi, Seyed Arash
    Safakhah, Mandana
    Moradi, Najmeh
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 543 - 554
  • [26] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [27] Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions
    Saw, Stephanie P. L.
    Ang, Mei-Kim
    Tan, Daniel S. W.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1721 - 1731
  • [28] Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Huo, Gengwei
    Song, Ying
    Liu, Wenjie
    Cao, Xuchen
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
    Shiozawa, Toshihiro
    Numata, Takeshi
    Tamura, Tomohiro
    Endo, Takeo
    Kaburagi, Takayuki
    Yamamoto, Yusuke
    Yamada, Hideyasu
    Kikuchi, Norihiro
    Saito, Kazuhito
    Inagaki, Masaharu
    Kurishima, Koichi
    Funayama, Yasunori
    Miyazaki, Kunihiko
    Koyama, Nobuyuki
    Furukawa, Kinya
    Nakamura, Hiroyuki
    Kikuchi, Shinji
    Ichimura, Hideo
    Sato, Yukio
    Sekine, Ikuo
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2022, 42 (05) : 2583 - 2590
  • [30] Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
    Felip, Enriqueta
    Metro, Giulio
    Soo, Ross A.
    Wolf, Juergen
    Solomon, Benjamin J.
    Tan, Daniel S. W.
    Ardizzoni, Andrea
    Lee, Dae Ho
    Sequist, Lecia V.
    Barlesi, Fabrice
    Ponce-Aix, Santiago
    Abreu, Delvys Rodriguez
    Campelo, Maria Rosario Garcia
    Sprauten, Mette
    Djentuh, Leslie O'Sullivan
    Smith, Nathalie
    Jary, Aline
    Belli, Riccardo
    Glaser, Sabine
    Zou, Mike
    Cui, Xiaoming
    Giovannini, Monica
    Yang, James Chih-Hsin
    EUROPEAN JOURNAL OF CANCER, 2024, 208
12345